Details of the Drug Combination

General Information of Drug Combination (ID: DCF0AQS)

Drug Combination Name

Vismodegib Uracil mustard

Indication

Disease Entry	Status	REF
Clear cell renal cell carcinoma	Investigative	[1]

Component Drugs

Vismodegib DM5IXKQ

Uracil mustard DMHL7OB

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: A498

Zero Interaction Potency (ZIP) Score: 5.49

Bliss Independence Score: 13.66

Loewe Additivity Score: 6.98

LHighest Single Agent (HSA) Score: 13.42

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Vismodegib

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Approved	[2]
Primitive neuroectodermal tumour medulloblastoma	2A00.11	Phase 2	[3]

Vismodegib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Smoothened homolog (SMO)	TT8J1S3	SMO_HUMAN	Modulator	[6]
------------------------------------------------------------------------------------

Vismodegib Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[7]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[7]
------------------------------------------------------------------------------------

Vismodegib Interacts with 13 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[8]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[8]
Zinc finger protein GLI1 (GLI1)	OT1BTAJO	GLI1_HUMAN	Decreases Expression	[8]
Zinc finger protein GLI2 (GLI2)	OTIRV97L	GLI2_HUMAN	Decreases Expression	[8]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[8]
Platelet-derived growth factor receptor alpha (PDGFRA)	OTDJXUCN	PGFRA_HUMAN	Decreases Expression	[8]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[8]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Cleavage	[8]
Protein patched homolog 1 (PTCH1)	OTMG07H5	PTC1_HUMAN	Decreases Expression	[8]
Protein smoothened (SMO)	OTXXE208	SMO_HUMAN	Decreases Expression	[8]
Protein patched homolog 2 (PTCH2)	OTOQ0K9V	PTC2_HUMAN	Decreases Expression	[8]
Suppressor of fused homolog (SUFU)	OT0IRYG1	SUFU_HUMAN	Decreases Response To Substance	[9]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Decreases Response To Substance	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DOT(s)

Indication(s) of Uracil mustard

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[4]
Chronic myelogenous leukaemia	2A20.0	Approved	[5]
Polycythemia vera	2A20.4	Approved	[5]
Small lymphocytic lymphoma	2A82.0	Approved	[5]

Uracil mustard Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[10]
------------------------------------------------------------------------------------

Uracil mustard Interacts with 5 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1)	OT7FBG5W	NAR1_HUMAN	Increases ADR	[11]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases ADR	[11]
Granulocyte-macrophage colony-stimulating factor (CSF2)	OT1M7D28	CSF2_HUMAN	Increases ADR	[11]
Poly polymerase 1 (PARP1)	OTIESHK4	PARP1_ARATH	Increases ADR	[11]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases ADR	[11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Colon carcinoma	DCQQHO5	KM12	Investigative	[12]
Invasive ductal carcinoma	DCASZAK	BT-549	Investigative	[12]
Adenocarcinoma	DCEOPJO	DU-145	Investigative	[1]
Adenocarcinoma	DCNDGM2	NCIH23	Investigative	[1]
Adenocarcinoma	DCHQQU9	HCT116	Investigative	[1]
Adult T acute lymphoblastic leukemia	DC6J8Z2	MOLT-4	Investigative	[1]
Astrocytoma	DC1TGRA	U251	Investigative	[1]
Astrocytoma	DCOZMV2	SNB-19	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DC2SEWV	CCRF-CEM	Investigative	[1]
Glioma	DCWXKAG	SF-295	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCODUXK	OVCAR-8	Investigative	[1]
Large cell lung carcinoma	DCF0PR5	NCI-H460	Investigative	[1]
Lung adenocarcinoma	DCHBA1X	EKVX	Investigative	[1]
Lung adenocarcinoma	DCDEN0E	MDA-MB-231	Investigative	[1]
Lung adenocarcinoma	DCOY1E8	NCI-H522	Investigative	[1]
Malignant melanoma	DC2TZAN	LOX IMVI	Investigative	[1]
Malignant melanoma	DCSR5JR	UACC62	Investigative	[1]
Melanoma	DCBLFU2	SK-MEL-2	Investigative	[1]
Non-small cell lung carcinoma	DCN5Q3Y	HOP-92	Investigative	[1]
Prostate carcinoma	DCHA8A8	PC-3	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
3	A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
5	Uracil mustard FDA Label
6	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
7	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
8	Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.
9	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul;20(7):732-40. doi: 10.1038/nm.3613. Epub 2014 Jun 29.
10	Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
11	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.